Vanguard Personalized Indexing Management LLC Has $8.90 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Vanguard Personalized Indexing Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 13.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 51,771 shares of the company’s stock after acquiring an additional 6,189 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Zoetis were worth $8,899,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Webster Bank N. A. lifted its holdings in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management acquired a new position in Zoetis in the fourth quarter valued at approximately $40,000. LRI Investments LLC acquired a new position in Zoetis in the first quarter valued at approximately $43,000. Ables Iannone Moore & Associates Inc. acquired a new stake in Zoetis in the fourth quarter worth $51,000. Finally, Hazlett Burt & Watson Inc. raised its holdings in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a report on Tuesday, August 27th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average target price of $217.11.

Zoetis Stock Up 0.8 %

Zoetis stock opened at $195.74 on Wednesday. The company has a market cap of $88.68 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a fifty day simple moving average of $183.65 and a 200 day simple moving average of $174.15. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.41 earnings per share. Research analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.